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Genome-wide association studies (GWAS) have provided valuable insights 14 
into the genetic basis of complex traits, discovering >6000 variants 15 
associated with >500 quantitative traits and common complex diseases in 16 
humans. The associations identified so far represent only a fraction of 17 
those which influence phenotype, as there are likely to be very many 18 
variants across the entire frequency spectrum, each of which influences 19 
multiple traits, with only a small average contribution to the phenotypic 20 
variance. This presents a considerable challenge to further dissection of 21 
the remaining unexplained genetic variance within populations, which 22 
limits our ability to predict disease risk, identify new drug targets, improve 23 
and maintain food sources, and understand natural diversity. This 24 
challenge will be met within the current framework through larger sample 25 
size, better phenotyping including recording of non-genetic risk factors, 26 
focused study designs, and an integration of multiple sources of phenotypic 27 
and genetic information. The current evidence supports the application of 28 
quantitative genetic approaches, and we argue that one should retain 29 
simpler theories until simplicity can be traded for greater explanatory 30 
power. 31 
 32 
The search for genetic variants 33 
The majority of biological phenotypes and many of the characters of interest to 34 
humans are complex in that they are determined by many mutations at multiple 35 
loci [1–8], as well as by many non-genetic factors. Some phenotypes show 36 
classical Mendelian patterns of inheritance and segregate within families [9–12]. 37 
However, for most traits, there is evidence that rare Mendelian mutations, low 38 
frequency segregating variants, copy number variants, and common variants all 39 
contribute toward complex phenotypes. Furthermore, across all species there is 40 
evidence of widespread pleiotropy across common diseases [13], quantitative 41 
phenotypes and Mendelian traits [14], meaning that each variant is likely to 42 
influence multiple phenotypes. The majority of current evidence is from humans 43 
(but see [8] for stature across a number of organisms), where the data for 44 
psychiatric disorders [4,15–18], diabetes [5], cardiovascular disease [19,20], 45 
obesity [21,22], and height [1] are consistent with a model where a large number 46 
of loci contribute predominantly additively to the phenotypic variation observed 47 
within populations [23–29].  48 
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 2 
Such a large mutational target in the genome has consequences for identifying 1 
new variants and for explaining the heritable genetic effects observed for the 2 
majority of phenotypes. As a large number of loci are likely to influence complex 3 
traits, then on average their contribution to the population-level variance will be 4 
small. The associations identified so far represent only a small fraction of those 5 
that influence a given phenotype, as evidenced by the fact that studies of 6 
increased range of allele frequency and sample size continue to detect additional 7 
variants, i.e. [4]. Here, we discuss how further dissection of the genetic variation 8 
for many complex traits will require larger sample size, better phenotyping 9 
including recording of non-genetic risk factors, focused study designs, and an 10 
integration of multiple sources of phenotypic and genetic information. Rather 11 
than continuing to evoke ever more complex esoteric arguments for the as yet 12 
unexplained heritable effects, we believe that current approaches in quantitative 13 
genetics coupled with gathering adequate data will dissect additional genetic 14 
variance within populations. The goal of explaining heritable effects is not purely 15 
academic. Until more of the variation expected from family studies is explained 16 
by direct analysis of the genome, there remains the possibility that we have a 17 
fundamental misunderstanding in our knowledge and conceptual framework. 18 
Identification of specific genomic variants that underpin individual differences 19 
provides the foundation for prediction, risk profiling and personalized medicine; 20 
for identifying pathways and new potential drug targets; for classifying disease 21 
subtypes; for improving and maintaining food sources; and for understanding 22 
the influence of selection and the maintenance of diversity in the natural world. 23 
 24 
Complex trait variation 25 
The genomic variation that we observe within a population is the result of the 26 
evolutionary forces of mutation, genetic drift, recombination, and natural 27 
selection in the evolutionary past [24], which is something that we do not know, 28 
particularly given the extent of pleiotropy across traits (Box 1). A wide range of 29 
genetic architectures, in terms of the exact number, effect size and frequency of 30 
causal variants may be consistent with current findings in humans [30]. Linkage 31 
studies and GWAS have identified many thousands of significant associations 32 
across more than 500 human phenotypes (Box 1), and it is clear that for any 33 
given trait, genetic variance is likely contributed from a large number of loci 34 
across the entire allele frequency spectrum.  35 
 36 
Some researchers suggest that ‘synthetic associations’, where associations at 37 
common SNPs reflect LD with multiple rare variants, underlie many GWAS 38 
results and that drawing conclusions regarding genetic architecture from GWAS 39 
is not justified [31,32]. Although there are examples of ‘synthetic associations’ 40 
[33], they cannot explain all GWAS results [3,34,35]. Converging lines of evidence 41 
suggest a contribution from variants of >5% frequency: (i) conditional and joint 42 
analyses dissect allelic heterogeneity and distinguish among independent 43 
association signals at common SNPs [1,33,35–38]; (ii) common variants have 44 
been functionally validated [39]; (iii) associations have been replicated across 45 
distinct populations [40]; and (iv) there is some evidence for polygenic 46 
adaptation, meaning that selection has acted to alter the frequency of many 47 
common variants [41]. As sample sizes increase, the number of identified 48 
genomic regions and the amount of variation explained by association studies 49 
 3 
has increased. For example, a recent GWAS meta-analysis for rheumatoid 1 
arthritis (RA) in a total of >100,000 subjects discovered 42 novel risk loci 2 
bringing the total at the time of writing to 101 [42]. Functional annotation, the 3 
overlapping of GWAS hits and cis-action eQTL, and pathway analysis identified 4 
98 biological candidate genes at the 101 risk loci. This GWAS study, as well as 5 
others, identifies a myriad of drug targets, which if verified, may be hugely 6 
effective because these regions are associated with RA across the majority of 7 
cases, rather than just a small number of families. GWAS has also identified new 8 
mechanisms involved in a range of diseases, such as autophagy of Crohn’s 9 
disease [43] and the role of lipid metabolism in Alzheimer’s [44]. It is clear that 10 
with sufficient sample size, large-scale association studies will shed light on 11 
fundamental genes, pathways and cell types involved in disease, and provides 12 
important information for drug discovery for treatments that are likely to be 13 
effective across many cases. 14 
 15 
For common disorders and complex phenotypes, variation will be attributable to 16 
both rare and commonly varying regions of the genome. Individual effect sizes at 17 
common loci are modest and each SNP explains little of the phenotypic variance 18 
(Box 1). When we take the effects of all common SNPs collectively, the narrow 19 
sense heritability expected from family studies is not captured through linkage 20 
disequilibrium (LD) with currently tagged common SNPs [28]. For height, where 21 
45% phenotypic variance is tagged by common SNPs, ~30% of genetic variation 22 
is still unexplained, and for many complex traits and diseases it appears that ½ 23 
to ⅔ of the genetic variance is not tagged by current and past SNP chips [1–24 
3,28,45]. These findings suggest that very many lower frequency variants are 25 
also needed to explain the genetic variance that is not tagged by current SNP 26 
chips. Using height as an example, we can model the expected number of variants 27 
that would be required to explain the remaining 30% of genetic variation, across 28 
a spectrum of low allele frequency and a range of effect sizes. Figure 1a shows 29 
that if the unexplained genetic variation for height can be attributed to low 30 
frequency variants, then a large number of segregating variants will exist even if 31 
their effect sizes on average are large.  32 
 33 
The combined contribution of multiple rare loci to the population-level genetic 34 
variance remains an open question because association studies that focus on 35 
rare (<1% MAF) variants remain underpowered. Mutation rates have been 36 
estimated as ~1.2 x 10-8 bp-1 generation-1 in humans [46–49], meaning that 37 
individuals will posses ~60-70 novel SNP alleles, one of which (on average) will 38 
be a coding variant. Therefore, within an expanding human population most 39 
segregating variants will be rare [50]. Lower frequency coding variants that have 40 
yet to be identified are predicted to include functional variants with larger 41 
effects on risk (Box 1) and may also be key targets for new drug therapies, such 42 
as with LDL cholesterol [51,52]. Rare mutations have been identified which 43 
influence complex traits [53–57]. For example, mutations in the FBN1 gene gives 44 
a 10-20cm increase in height [58], and for schizophrenia a deletion at chr22q11 45 
give an odds ratio of ~20 [59,60]. However, large effect sizes or odds ratios do 46 
not equate to a large contribution to the variance explained at the population-47 
level. Even at a frequency of 10-4 (1 in 10,000) a mutation within a gene that has 48 
a large effect size of 2SD will only explain 8 x 10-4 of the phenotypic variance of a 49 
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complex trait within a population. Correspondingly, FBN1 and the chr22q11 1 
deletion explain 0.2 and 0.1% of the variation of height and schizophrenia 2 
respectively. Even more powerful recent whole exome sequencing (WES) studies 3 
of schizophrenia at the population-level [61], and Alzheimer’s disease within 4 
families [62], identified enrichment for rare variants, but this early work 5 
suggests a large polygenic burden of rare coding variants which alone may not 6 
account for the unexplained variation. Generally, rare variant association studies 7 
have found variants with large odds ratios which each explain only a tiny 8 
proportion of the phenotypic variance [63,64].  9 
 10 
Given the likely large mutational target size for complex traits, with variation 11 
contributed across the entire allele frequency spectrum, it will be a significant 12 
challenge to identify all of the variants involved. Many researchers have 13 
questioned the need to explain genetic variation at the population-level, debated 14 
the usefulness of association studies, or even challenged the general application 15 
of quantitative genetic approaches to understanding complex trait variation 16 
[31,54,65–67], which is in our view is unjustified. Firstly, with the exception of 17 
very rare Mendelian traits, it makes little sense to focus only on affected families. 18 
The majority of complex traits will have a highly polygenic architecture which is 19 
consistent with (i) the existence of Mendelian forms in a small number of cases 20 
within a population, (ii) with common occurrences in families with no previous 21 
history [68], and (iii) with any two individuals carrying different sets of risk 22 
alleles (often termed ‘genetic heterogeneity’). High polygenicity and a large 23 
number of non-Mendelian mutations imply that variants segregate across 24 
families and thus nuclear families are no longer a natural unit. Family studies 25 
will compliment GWAS and will identify rare and de novo mutations in specific 26 
cases, but they will explain little of the variation in cases across the population as 27 
a whole, because there will be very many rare variants involved. Secondly, 28 
quantitative genetic theory does not make any assumptions about genetic 29 
architecture, which makes it a useful statistical description of the phenotypic 30 
data in pedigrees and populations. The evidence supports its application, it can 31 
accommodate non-additive effects, estimate interactions of higher orders, and it 32 
makes predictions that can be tested empirically (Box 2). Therefore this is not an 33 
either-or debate [69], and advocating a focus on solely rare or common variants 34 
will not be a productive way forward. Explaining genetic variance for complex 35 
traits will require a combination of large-scale GWAS and large-scale more 36 
targeted approaches at both the population and family-level to identify the 37 
remaining genetic variants.  38 
 39 
Dissecting more of the genetic variance 40 
Epistasis, de novo mutations, or epigenetic effects are unlikely to be the 41 
explanation for the ‘missing heritability’. Appreciable epistatic variance is 42 
unlikely because most alleles will be rare and allelic substitutions have near 43 
additive effects, meaning that additivity in quantitative genetic statistical models 44 
is not inconsistent with epistasis commonly observed at the functional cellular 45 
level [25,70]. De novo mutations are not inherited by definition and so do not 46 
contribute to heritability [71] - in family studies their effects would be 47 
partitioned into a unique environmental variance component. Finally, inherited 48 
 5 
epigenetic effects would behave the same as a SNP in GWAS. Thus, a number of 1 
alternative explanations are more likely.  2 
 3 
Firstly, as we have seen with rare variants, although effect sizes may be larger 4 
than for common variants, the variance explained at the population level by 5 
alleles of frequency <5% will be small, meaning that very large sample sizes are 6 
likely to be needed. Even when considering transmission within-families, which 7 
are likely to complement association studies, large numbers of families will be 8 
required [72]. Second, these variants are less likely to be in strong LD with 9 
common variants that are tagged on current SNP chips because (i) they may be 10 
under stronger selection and therefore be younger polymorphisms with lower 11 
minor allele frequency; and (ii) many may be deletions or duplications (i.e. 12 
CNVs) which interfere with the ability to assay SNPs near enough to be in strong 13 
LD [73]. Third, our phenotyping may be inaccurate such that we are combining 14 
phenotypes or diseases that have partially or even completely distinct 15 
underlying causal variants. This will average effect sizes across groups of 16 
individuals, who could be better separated on the basis of better phenotyping or 17 
a combination of information from different sources. Addressing these three 18 
issues is a far more pragmatic approach that will contribute significantly to 19 
identifying additional variants and explaining a larger portion of the genetic 20 
variance.  21 
 22 
Power, sample size, and study design 23 
The first step is increasing the number of individuals within a sample. The 24 
number of well-characterized phenotypic samples often limits sample sizes in 25 
GWAS. Power to link genotype to phenotype is a function of the set of SNPs on a 26 
chip, effect size, and sample size, and can be assessed analytically or through 27 
simulation. For ascertained case control disease studies, under a liability 28 
threshold model the expected chi-squared test statistic 𝜒2has a known analytic 29 
relationship 𝔼 [𝜒2] ∝ 𝑁𝛾2𝑝(1 − 𝑝)𝑟2 where N is the sample size, 𝛾 is the effect 30 
size, 𝑝 is the allele frequency, and 𝑟2 is the correlation between the marker and 31 
the causal SNP [30]. Given the potentially large number of causal variants of 32 
frequency <5% that each explain little of the variance, then even if the variant is 33 
in complete LD with a genotyped SNP, and sample sizes are large there is 34 
currently low power to dissect additional genetic variation (Fig 1b). Figure 1b 35 
shows the power to detect variants that explain a small percentage of disease 36 
liability, which decreases rapidly for variants that explain <0.2% of the variance 37 
even with 10,000 cases and 10,000 matched controls.  38 
 39 
Increasing sample size will have the greatest effect on power. Replacing high 40 
density SNP chips with full sequencing will tag low frequency loci, but it will not 41 
be enough alone to capture the effects of rare variants, because many rare 42 
variants will be at such low number that very large data-sets are is required for 43 
their detection. A recent whole-exome sequencing study for schizophrenia [61] 44 
provides an example, as it suggests evidence for a polygenic burden of rare 45 
variants, but was not successful in identifying individually significantly enriched 46 
genes. As large-scale parallel-sequencing studies of many thousands of 47 
individuals becomes common-place then sufficient power is likely to be gained, 48 
allowing both rare and common variants to be dissected to a far greater extent. 49 
 6 
This leaves only a choice of experimental design. Focused study designs will help 1 
in the identification of additional variants; using densely affected families will 2 
identify additional rare variants which can be followed-up with a combination of 3 
genotyping and deep re-sequencing of the variants or genes of interest in large 4 
numbers of cases and controls. However, as evidence by a recent Alzheimer’s 5 
study which identified only a single region [62], this study design also requires 6 
large sample size to distinguish signal from chance co-segregation. 7 
 8 
Improvements to phenotyping 9 
For all genetic studies, more samples have to go hand-in-hand with better 10 
phenotyping, but this is easier said than done. In general, genome analyses of a 11 
wider range of phenotypes across a wide range of species is required if we are to 12 
improve our understanding of the relationship between selection and genetic 13 
architecture. Many of our current phenotypes are subjectively measured and 14 
may represent many underlying biological processes. For example, many 15 
psychiatric disorders are diagnosed on a complex range of overlapping clinical 16 
characteristics [74], type-2 diabetes is diagnosed using a blood glucose threshold 17 
[75], metabolic syndrome is based on observing three of five criteria [76], and 18 
even many quantitative traits are arbitrary metrics or defined as functions of 19 
other characters. Misclassifying a phenotype, especially when multiple distinct 20 
phenotypes are influenced by different sets of underlying causal variants, can 21 
reduce power in GWAS relative to expectation based on power calculations of 22 
idealized homogeneous populations. Strong genotypic effects important in a 23 
small homogeneous sub-group could have a very small or even negligible effect 24 
within an entire population. These effects are prominent in cancers in which 25 
molecular subtypes have been identified such as ER +ve/–ve status HER2 26 
expression in breast-cancer [77,78], or K-ras mutations in colorectal cancer and 27 
EGFR mutations in lung cancer, reviewed in [79]. If true for other complex 28 
phenotypes, then a single univariate measure may be unrepresentative of the 29 
biological etiology, and breaking the phenotype down into sub-phenotypes may 30 
reveal additional variants. 31 
 32 
One approach to this may be to use additional phenotypic information collected 33 
on the same subjects. For many disease phenotypes, age-at-onset varies across 34 
subjects and could be used as a classifying term. Modeling can then be done by 35 
dividing cases into sub-groups, or by estimating genetic effects as a function 36 
across age-at-onset (for an example see [80]). Additionally, phenotypes could be 37 
stratified across the values of another associated phenotype, as has been done 38 
with T2D and BMI [81].  Insight may also be gained from adopting a multivariate 39 
approach, where jointly modeling multiple traits can give higher power than 40 
standard univariate GWAS [82]. There may be differing underlying effect sizes, 41 
or even different causal variants, depending upon the onset of a disease, or upon 42 
the values of another component of phenotype, which are more likely to be 43 
detected with these approaches. When only a single phenotypic measure is 44 
available for a given sample, mixture models may enable causal variants 45 
associated with phenotypic heterogeneity to be identified [83], but these models 46 
remain little explored and have yet to be applied in any great detail in GWAS. 47 
 48 
 7 
Using clinical classifications and finer scale diagnoses rather than a simple case-1 
control status can also serve the same purpose, as reviewed in [84]. The use of 2 
endophenotypes - intermediate or underlying phenotypic components that form 3 
the expression of a trait or disorder - may also be useful for dissecting additional 4 
genetic variation. For example in psychiatric disorders, different causal variants 5 
may influence multiple neural systems differentially [85–87]. Provided these 6 
endophenotypes are heritable, numerous, vary continuously, and are associated 7 
with the cause rather than the effect of the disease, GWAS on these more direct 8 
physiological or anatomical assessments may dissect additional genetic variation 9 
(for example [88]). Endophenotypes may be equally as complex as the complex 10 
traits they aim to reflect, but the use of endophenotypes within a multivariate 11 
analysis framework may enable genetic covariance to be partitioned across 12 
different shared and independent underlying pathways as a mechanism to 13 
dissect the etiology of complex diseases. Functional genomic profiling of serum 14 
or tissue, etiology-specific functional assays, and improved phenotypic assays 15 
maximizing information content will enable more rigorous genetics provided 16 
that candidate phenotypes are readily scalable and robust enough to provide 17 
accurate measures under routine data collection. There is a general perception 18 
that the study of endophenotypes has delivered less than it promised, but this 19 
may be because samples sizes are often very limited. As larger samples are 20 
collected it seems inappropriate to not accompany this with more detailed 21 
phenotyping to allow fully powered interrogation of clinical phenotypic 22 
heterogeneity. 23 
 24 
Linking component information together 25 
Overlapping GWAS results with other genomic sources of information is likely to 26 
explain additional variation and identify novel pathways. Studies have shown 27 
that ‘all SNPs are not created equal’, with functional SNPs being more frequently 28 
associated with phenotypes [89]. For example, chromatin marks (modifications 29 
of proteins that package DNA) were once dismissed as ‘junk DNA’, but are now 30 
thought to fulfill regulatory functions. GWAS results cluster near chromatin 31 
marks more frequently in certain cell types, enabling genetic variation to be 32 
apportioned to different cell types and regulatory pathways involved in disease 33 
expression [90]. The targeting of expression SNPs and the linking of GWAS, gene 34 
expression, and methylation data has uncovered additional variants and 35 
provided direct information on the underlying biology of complex phenotypes 36 
[91].  37 
 38 
These approaches may also help us to understand whether genetic associations 39 
among traits represents gene expression that is shared, or whether the same 40 
variant contributes to variation in expression in different tissues that affect 41 
different traits. Additionally, leveraging this information to inform prior 42 
probability of SNP association within a Bayesian GWAS framework may also 43 
enable additional variants to be detected [92]. Thus far, integrative analyses 44 
within a systems genetics approach have largely focused on validated SNPs. 45 
Using a broader set of variants by integrating genome sequencing and cellular 46 
phenotype data will help to pinpoint putative causal genetic variants underlying 47 
GWAS associations and enable a better understanding of the biological basis of 48 
phenotype.  49 
 8 
 1 
Using additional genomic variation 2 
Copy number variations (CNVs) represent a significant source of genetic 3 
variation affecting ~12% of the human genome. CNVs may influence gene 4 
function and thus complex phenotypes through gene dosage imbalances, altered 5 
messenger RNA (mRNA) expression levels, or through the expression of 6 
truncated proteins [93]. Studies have demonstrated associations with both rare 7 
and common CNVs with several complex phenotypes including schizophrenia 8 
and autism [94,95] and a focus on intermediate frequency CNVs may yield 9 
additional associations.  10 
 11 
In most GWAS, analysis is also largely confined to the nuclear genome, with 12 
much less attention paid to the organellar genome (mitochondrial DNA). This is 13 
in contrast to the central role that the organellar genome plays in controlling 14 
organismal metabolism and function, and increasing evidence from other non-15 
human organisms that mitochondrial genomic variation can modulate the effects 16 
of nuclear genomic variation (although see [96]). Genomic variation in human 17 
mitochondria has been linked to several severe diseases, and more recently 18 
quantitative studies of common human diseases have suggested that genetic 19 
variation in organellar genomes may modify the effects of nuclear loci [97]. 20 
Including imputed mtDNA in GWAS may also yield additional variants especially 21 
if interactions between nuclear and cytoplasmic effects are estimated. 22 
 23 
Improved analysis methods 24 
In standard analysis of GWAS effects are estimated one marker at a time, but 25 
fitting multiple SNPs together may improve ability to dissect additive genetic 26 
variation across the genome. Multiple SNP effects can be fitted at the discovery 27 
stage to estimate genome-wide heritability across SNPs of different frequency, 28 
across segments of the genome (termed ‘regional heritability’), or in gene sets 29 
[98], and these methods have been shown to capture additional genetic variance 30 
[2,13,29], and even multiple independent variants within genomic regions [99]. 31 
At the meta-analysis stage, conditional analyses and multi-SNP association 32 
methods can also be used [100,101]. There are many known examples of 33 
multiple semi-independent associations at individual loci; such associations 34 
might arise either because of true allelic heterogeneity or because of imperfect 35 
tagging of an unobserved causal variant, and these approaches have used GWAS 36 
summary statistics to estimate the effect of loci harboring multiple association 37 
signals [100,101], which has explained additional genetic variation for many 38 
phenotypes. 39 
 40 
In additional to the power gained [82], adopting a multivariate approach allows 41 
an estimation of the amount co-heritability, or pleiotropy across traits. 42 
Associations among multiple morphological phenotypes and among psychiatric 43 
diseases at common SNPs have been identified which further supports the role of 44 
common SNPs in complex trait variation [13,27]. At the phenotypic level there is 45 
evidence of associations between Mendelian disorders and between Mendelian 46 
and complex diseases [14], which can be better understood by examining genetic 47 
correlations among phenotypes across the genome.  48 
 49 
 9 
Additional extensions to current models may also include the estimation of non-1 
additive effects such as dominance and epistasis [102]; estimation of maternal 2 
effects in data where maternal genotypes are known [103]; and genotype-3 
environment interactions [104]. Although each of these sources may only 4 
contribute to the variance of complex traits to a small degree, the variance 5 
attributed to these effects across all SNPs can be estimated. Ultimately with the 6 
plummeting costs of DNA sequencing, GWAS will employ direct DNA sequencing. 7 
Even though this will allow tests of association for low frequency variants, rare 8 
variants occur too infrequently to allow for individual associations to be tested 9 
and require aggregating variants into sets and comparing frequencies [105]. All 10 
genetic studies, whether common and rare variant association studies, or within 11 
family studies, require large samples size and well-defined phenotypes if we are 12 
to fully dissect heritable genetic variation. 13 
 14 
Concluding remarks 15 
The evidence to date shows that complex trait variation is due to very many loci 16 
contributed throughout the genome and across the allele frequency spectrum, 17 
each of which influences multiple phenotypes, and makes a small average 18 
contribution to the variance. Many authors, both in the early days of GWAS and 19 
more recently, have argued that GWAS has yet to dissect all of the expected 20 
genetic variance and that because many genes in a large number of distinct 21 
genomic regions have been detected, which are likely to show functional 22 
epistasis, a paradigm shift is required in order to link genotype to phenotype and 23 
dissect genetic variation. We feel that this is unnecessary (Box 2), and we believe 24 
that in humans, as well as in other species, the current framework, coupled with 25 
studies designed to identify rare variants will dissect the genetic variation of a 26 
wide range of complex traits. These steps will improve our ability to predict 27 
disease risk, identify new drug targets, improve and maintain food sources, and 28 
to understand diversity of the natural world. 29 
 30 
Acknowledgements 31 
We acknowledge support from the Australian Research Council (FT0991360, 32 
DP130102666), the Australian National Health and Medical Research Council 33 
(APP1011506, APP1047956, APP1048853, APP1050218, APP1047956, APP613601 34 
APP613602) and the National Institutes of Health (GM099568, GM075091, 35 
MH100141). The content is solely the responsibility of the authors and does not 36 
necessarily represent the official view of the funding bodies. 37 
 38 
 39 
References  40 
1  Lango Allen, H. et al. (2010) Hundreds of variants clustered in genomic loci 41 
and biological pathways affect human height. Nature 467, 832–8 42 
2  Lee, S.H. et al. (2012) Estimating the proportion of variation in 43 
susceptibility to schizophrenia captured by common SNPs. Nat. Genet. 44, 44 
247–50 45 
 10 
3  Visscher, P.M. et al. (2012) Five years of GWAS discovery. Am. J. Hum. 1 
Genet. 90, 7–24 2 
4  Ripke, S. et al. (2013) Genome-wide association analysis identifies 13 new 3 
risk loci for schizophrenia. Nat. Genet. 45, 1150–9 4 
5  Morris, A.P. et al. (2012) Large-scale association analysis provides insights 5 
into the genetic architecture and pathophysiology of type 2 diabetes. Nat. 6 
Genet. 44, 981–90 7 
6  Schunkert, H. et al. (2011) Large-scale association analysis identifies 13 8 
new susceptibility loci for coronary artery disease. Nat. Genet. 43, 333–8 9 
7  Teslovich, T.M. et al. (2010) Biological, clinical and population relevance of 10 
95 loci for blood lipids. Nature 466, 707–13 11 
8  Kemper, K.E. and Goddard, M.E. (2012) Understanding and predicting 12 
complex traits: knowledge from cattle. Hum. Mol. Genet. 21, R45–51 13 
9  Scriver, C.R. (2007) The PAH gene, phenylketonuria, and a paradigm shift. 14 
Hum. Mutat. 28, 831–45 15 
10  Sosnay, P.R. et al. (2013) Defining the disease liability of variants in the 16 
cystic fibrosis transmembrane conductance regulator gene. Nat. Genet. 45, 17 
1160–7 18 
11  MacDonald, M.E. et al. (1993) A novel gene containing a trinucleotide 19 
repeat that is expanded and unstable on Huntington’s disease 20 
chromosomes. Cell 72, 971–983 21 
12  Steinberg, M.H. and Rodgers, G.P. (2001) Pathophysiology of sickle cell 22 
disease: role of cellular and genetic modifiers. Semin. Hematol. 38, 299–23 
306 24 
13  Lee, S.H. et al. (2013) Genetic relationship between five psychiatric 25 
disorders estimated from genome-wide SNPs. Nat. Genet. 45, 984–94 26 
14  Blair, D.R. et al. (2013) A nondegenerate code of deleterious variants in 27 
Mendelian loci contributes to complex disease risk. Cell 155, 70–80 28 
15  Sklar, P. et al. (2011) Large-scale genome-wide association analysis of 29 
bipolar disorder identifies a new susceptibility locus near ODZ4. Nat. 30 
Genet. 43, 977–83 31 
16  Connolly, J.J. et al. (2013) A genome-wide association study of autism 32 
incorporating autism diagnostic interview-revised, autism diagnostic 33 
observation schedule, and social responsiveness scale. Child Dev. 84, 17–34 
33 35 
 11 
17  Neale, B.M. et al. (2010) Meta-analysis of genome-wide association studies 1 
of attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. 2 
Psychiatry 49, 884–97 3 
18  Ripke, S. et al. (2013) A mega-analysis of genome-wide association studies 4 
for major depressive disorder. Mol. Psychiatry 18, 497–511 5 
19  Cordell, H.J. et al. (2013) Genome-wide association study of multiple 6 
congenital heart disease phenotypes identifies a susceptibility locus for 7 
atrial septal defect at chromosome 4p16. Nat. Genet. 45, 822–4 8 
20  Lettre, G. et al. (2011) Genome-wide association study of coronary heart 9 
disease and its risk factors in 8,090 African Americans: the NHLBI CARe 10 
Project. PLoS Genet. 7, e1001300 11 
21  Yang, J. et al. (2012) FTO genotype is associated with phenotypic 12 
variability of body mass index. Nature 490, 267–72 13 
22  Speliotes, E.K. et al. (2010) Association analyses of 249,796 individuals 14 
reveal 18 new loci associated with body mass index. Nat. Genet. 42, 937–15 
48 16 
23  Bloom, J.S. et al. (2013) Finding the sources of missing heritability in a 17 
yeast cross. Nature 494, 234–7 18 
24  Eyre-Walker, A. (2010) Evolution in health and medicine Sackler 19 
colloquium: Genetic architecture of a complex trait and its implications for 20 
fitness and genome-wide association studies. Proc. Natl. Acad. Sci. U. S. A. 21 
107 Suppl , 1752–6 22 
25  Hill, W.G. et al. (2008) Data and theory point to mainly additive genetic 23 
variance for complex traits. PLoS Genet. 4, e1000008 24 
26  Stahl, E.A. et al. (2012) Bayesian inference analyses of the polygenic 25 
architecture of rheumatoid arthritis. Nat. Genet. 44, 483–9 26 
27  Vattikuti, S. et al. (2012) Heritability and genetic correlations explained by 27 
common SNPs for metabolic syndrome traits. PLoS Genet. 8, e1002637 28 
28  Yang, J. et al. (2010) Common SNPs explain a large proportion of the 29 
heritability for human height. Nat. Genet. 42, 565–9 30 
29  Yang, J. et al. (2013) Ubiquitous polygenicity of human complex traits: 31 
genome-wide analysis of 49 traits in Koreans. PLoS Genet. 9, e1003355 32 
30  Agarwala, V. et al. (2013) Evaluating empirical bounds on complex disease 33 
genetic architecture. Nat. Genet. advance on,  34 
 12 
31  Dickson, S.P. et al. (2010) Rare variants create synthetic genome-wide 1 
associations. PLoS Biol. 8, e1000294 2 
32  Mitchell, K.J. (2012) What is complex about complex disorders? Genome 3 
Biol. 13, 237 4 
33  Wang, K. et al. (2010) Interpretation of association signals and 5 
identification of causal variants from genome-wide association studies. 6 
Am. J. Hum. Genet. 86, 730–42 7 
34  Wray, N.R. et al. (2011) Synthetic associations created by rare variants do 8 
not explain most GWAS results. PLoS Biol. 9, e1000579 9 
35  Anderson, C.A. et al. (2011) Synthetic associations are unlikely to account 10 
for many common disease genome-wide association signals. PLoS Biol. 9, 11 
e1000580 12 
36  Medina-Gomez, C. et al. (2012) Meta-analysis of genome-wide scans for 13 
total body BMD in children and adults reveals allelic heterogeneity and 14 
age-specific effects at the WNT16 locus. PLoS Genet. 8, e1002718 15 
37  Park, J.-H. et al. (2011) Distribution of allele frequencies and effect sizes 16 
and their interrelationships for common genetic susceptibility variants. 17 
Proc. Natl. Acad. Sci. U. S. A. 108, 18026–31 18 
38  Flister, M.J. et al. (2013) Identifying multiple causative genes at a single 19 
GWAS locus. Genome Res. DOI: 10.1101/gr.160283.113 20 
39  Stranger, B.E. et al. (2011) Progress and promise of genome-wide 21 
association studies for human complex trait genetics. Genetics 187, 367–83 22 
40  Carlson, C.S. et al. (2013) Generalization and Dilution of Association 23 
Results from European GWAS in Populations of Non-European Ancestry: 24 
The PAGE Study. PLoS Biol. 11, e1001661 25 
41  Pritchard, J.K. et al. (2010) The genetics of human adaptation: hard 26 
sweeps, soft sweeps, and polygenic adaptation. Curr. Biol. 20, R208–15 27 
42  Okada, Y. et al. (2013) Genetics of rheumatoid arthritis contributes to 28 
biology and drug discovery. Nature advance on,  29 
43  Parkes, M. et al. (2007) Sequence variants in the autophagy gene IRGM and 30 
multiple other replicating loci contribute to Crohn’s disease susceptibility. 31 
Nat. Genet. 39, 830–2 32 
44  Di Paolo, G. and Kim, T.-W. (2011) Linking lipids to Alzheimer’s disease: 33 
cholesterol and beyond. Nat. Rev. Neurosci. 12, 284–96 34 
 13 
45  Manolio, T.A. et al. (2009) Finding the missing heritability of complex 1 
diseases. Nature 461, 747–53 2 
46  Abecasis, G.R. et al. (2010) A map of human genome variation from 3 
population-scale sequencing. Nature 467, 1061–73 4 
47  Awadalla, P. et al. (2010) Direct measure of the de novo mutation rate in 5 
autism and schizophrenia cohorts. Am. J. Hum. Genet. 87, 316–24 6 
48  Roach, J.C. et al. (2010) Analysis of genetic inheritance in a family quartet 7 
by whole-genome sequencing. Science 328, 636–9 8 
49  Kong, A. et al. (2012) Rate of de novo mutations and the importance of 9 
father’s age to disease risk. Nature 488, 471–5 10 
50  Gazave, E. et al. (2013) Population growth inflates the per-individual 11 
number of deleterious mutations and reduces their mean effect. Genetics 12 
195, 969–78 13 
51  Cohen, J. et al. (2005) Low LDL cholesterol in individuals of African 14 
descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 15 
37, 161–5 16 
52  Cohen, J.C. et al. (2006) Sequence variations in PCSK9, low LDL, and 17 
protection against coronary heart disease. N. Engl. J. Med. 354, 1264–72 18 
53  Dauber, A. et al. (2011) Genome-wide association of copy-number 19 
variation reveals an association between short stature and the presence of 20 
low-frequency genomic deletions. Am. J. Hum. Genet. 89, 751–9 21 
54  Kirov, G. et al. (2012) De novo CNV analysis implicates specific 22 
abnormalities of postsynaptic signalling complexes in the pathogenesis of 23 
schizophrenia. Mol. Psychiatry 17, 142–53 24 
55  Malhotra, D. et al. (2011) High frequencies of de novo CNVs in bipolar 25 
disorder and schizophrenia. Neuron 72, 951–63 26 
56  Ashley, E.A. et al. (2010) Clinical assessment incorporating a personal 27 
genome. Lancet 375, 1525–35 28 
57  Worthey, E.A. et al. (2011) Making a definitive diagnosis: successful 29 
clinical application of whole exome sequencing in a child with intractable 30 
inflammatory bowel disease. Genet. Med. 13, 255–62 31 
58  Nijbroek, G. et al. (1995) Fifteen novel FBN1 mutations causing Marfan 32 
syndrome detected by heteroduplex analysis of genomic amplicons. Am. J. 33 
Hum. Genet. 57, 8–21 34 
 14 
59  Murphy, K.C. et al. (1999) High rates of schizophrenia in adults with velo-1 
cardio-facial syndrome. Arch. Gen. Psychiatry 56, 940–5 2 
60  Williams, H.J. et al. (2013) Schizophrenia two-hit hypothesis in velo-cardio 3 
facial syndrome. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 162B, 177–82 4 
61  Purcell, S.M. et al. (2014) A polygenic burden of rare disruptive mutations 5 
in schizophrenia. Nature advance on,  6 
62  Cruchaga, C. et al. (2013) Rare coding variants in the phospholipase D3 7 
gene confer risk for Alzheimer’s disease. Nature 505, 550–554 8 
63  Bonnefond, A. et al. (2012) Rare MTNR1B variants impairing melatonin 9 
receptor 1B function contribute to type 2 diabetes. Nat. Genet. 44, 297–301 10 
64  Ji, W. et al. (2008) Rare independent mutations in renal salt handling genes 11 
contribute to blood pressure variation. Nat. Genet. 40, 592–9 12 
65  Mitchell, K.J. and Porteous, D.J. (2011) Rethinking the genetic architecture 13 
of schizophrenia. Psychol. Med. 41, 19–32 14 
66  Mitchell, K.J. (2012) What is complex about complex disorders? Genome 15 
Biol. 13, 237 16 
67  Nelson, R.M. et al. (2013) A century after Fisher: time for a new paradigm 17 
in quantitative genetics. Trends Genet. 29, 669–76 18 
68  Yang, J. et al. (2010) Sporadic cases are the norm for complex disease. Eur. 19 
J. Hum. Genet. 18, 1039–43 20 
69  Visscher, P.M. et al. (2012) Evidence-based psychiatric genetics, AKA the 21 
false dichotomy between common and rare variant hypotheses. Mol. 22 
Psychiatry 17, 474–85 23 
70  Barton, N.H. and Keightley, P.D. (2002) Understanding quantitative genetic 24 
variation. Nat. Rev. Genet. 3, 11–21 25 
71  Gratten, J. et al. (2013) Interpreting the role of de novo protein-coding 26 
mutations in neuropsychiatric disease. Nat. Genet. 45, 234–8 27 
72  Cheng, K.-F. and Chen, J.-H. (2013) Detecting rare variants in case-parents 28 
association studies. PLoS One 8, e74310 29 
73  Hannan, A.J. (2010) TRPing Up the Genome: Tandem Repeat 30 
Polymorphisms as Dynamic Sources of Genetic Variability in Health and 31 
Disease. Discov. Med. 10, 314–321 32 
74  Kapur, S. et al. (2012) Why has it taken so long for biological psychiatry to 33 
develop clinical tests and what to do about it? Mol. Psychiatry 17, 1174–9 34 
 15 
75  Xu, M. et al. The New Perspectives on Genetic Studies of Type 2 Diabetes 1 
and Thyroid Diseases. Bentham Science Publishers 2 
76  Fall, T. and Ingelsson, E. (2012) Genome-wide association studies of 3 
obesity and metabolic syndrome. Mol. Cell. Endocrinol. 382, 740–57 4 
77  Wang, Y. et al. Gene-expression profiles to predict distant metastasis of 5 
lymph-node-negative primary breast cancer. Lancet 365, 671–9 6 
78  Slamon, D.J. et al. (1987) Human breast cancer: correlation of relapse and 7 
survival with amplification of the HER-2/neu oncogene. Science 235, 177–8 
82 9 
79  Ferraldeschi, R. and Newman, W.G. (2011) Pharmacogenetics and 10 
pharmacogenomics: a clinical reality. Ann. Clin. Biochem. 48, 410–7 11 
80  Traylor, M. et al. (2013) Using phenotypic heterogeneity to increase the 12 
power of genome-wide association studies: application to age at onset of 13 
ischaemic stroke subphenotypes. Genet. Epidemiol. 37, 495–503 14 
81  Perry, J.R.B. et al. (2012) Stratifying type 2 diabetes cases by BMI identifies 15 
genetic risk variants in LAMA1 and enrichment for risk variants in lean 16 
compared to obese cases. PLoS Genet. 8, e1002741 17 
82  O’Reilly, P.F. et al. (2012) MultiPhen: joint model of multiple phenotypes 18 
can increase discovery in GWAS. PLoS One 7, e34861 19 
83  Warde-Farley, D. et al. (2012) Mixture model for sub-phenotyping in 20 
GWAS. Pac. Symp. Biocomput. at 21 
<http://www.ncbi.nlm.nih.gov/pubmed/22174291> 22 
84  Hall, M.-H. and Smoller, J.W. A new role for endophenotypes in the GWAS 23 
era: functional characterization of risk variants. Harv. Rev. Psychiatry 18, 24 
67–74 25 
85  Greenwood, T.A. et al. (2013) Genome-wide linkage analyses of 12 26 
endophenotypes for schizophrenia from the Consortium on the Genetics of 27 
Schizophrenia. Am. J. Psychiatry 170, 521–32 28 
86  Braff, D.L. et al. (2007) Deconstructing schizophrenia: an overview of the 29 
use of endophenotypes in order to understand a complex disorder. 30 
Schizophr. Bull. 33, 21–32 31 
87  Van Dongen, J. and Boomsma, D.I. (2013) The evolutionary paradox and 32 
the missing heritability of schizophrenia. Am. J. Med. Genet. B. 33 
Neuropsychiatr. Genet. 162B, 122–36 34 
88  Cruchaga, C. et al. (2013) GWAS of cerebrospinal fluid tau levels identifies 35 
risk variants for Alzheimer’s disease. Neuron 78, 256–68 36 
 16 
89  Schork, A.J. et al. (2013) All SNPs are not created equal: genome-wide 1 
association studies reveal a consistent pattern of enrichment among 2 
functionally annotated SNPs. PLoS Genet. 9, e1003449 3 
90  Trynka, G. et al. (2013) Chromatin marks identify critical cell types for fine 4 
mapping complex trait variants. Nat. Genet. 45, 124–30 5 
91  Edwards, S.L. et al. (2013) Beyond GWASs: Illuminating the Dark Road 6 
from Association to Function. Am. J. Hum. Genet. 93, 779–797 7 
92  Knight, J. et al. (2011) Using functional annotation for the empirical 8 
determination of Bayes Factors for genome-wide association study 9 
analysis. PLoS One 6, e14808 10 
93  Henrichsen, C.N. et al. (2009) Copy number variants, diseases and gene 11 
expression. Hum. Mol. Genet. 18, R1–8 12 
94  Pinto, D. et al. (2010) Functional impact of global rare copy number 13 
variation in autism spectrum disorders. Nature 466, 368–72 14 
95  Levinson, D.F. et al. (2011) Copy number variants in schizophrenia: 15 
confirmation of five previous findings and new evidence for 3q29 16 
microdeletions and VIPR2 duplications. Am. J. Psychiatry 168, 302–16 17 
96  Joseph, B. et al. (2013) Cytoplasmic genetic variation and extensive 18 
cytonuclear interactions influence natural variation in the metabolome. 19 
Elife 2, e00776 20 
97  Samuels, D.C. et al. (2013) Recurrent Tissue-Specific mtDNA Mutations Are 21 
Common in Humans. PLoS Genet. 9, e1003929 22 
98  Wang, L. et al. (2011) Gene set analysis of genome-wide association 23 
studies: Methodological issues and perspectives. Genomics 98, 1–8 24 
99  Uemoto, Y. et al. (2013) The power of regional heritability analysis for rare 25 
and common variant detection: simulations and application to eye 26 
biometrical traits. Front. Genet. 4, 232 27 
100  Ehret, G.B. et al. (2012) A multi-SNP locus-association method reveals a 28 
substantial fraction of the missing heritability. Am. J. Hum. Genet. 91, 863–29 
71 30 
101  Yang, J. et al. (2012) Conditional and joint multiple-SNP analysis of GWAS 31 
summary statistics identifies additional variants influencing complex 32 
traits. Nat. Genet. 44, 369–375 33 
102  Hemani, G. et al. (2013) An evolutionary perspective on epistasis and the 34 
missing heritability. PLoS Genet. 9, e1003295 35 
 17 
103  Buyske, S. (2008) Maternal genotype effects can alias case genotype effects 1 
in case-control studies. Eur. J. Hum. Genet. 16, 783–5 2 
104  Thomas, D. (2010) Methods for investigating gene-environment 3 
interactions in candidate pathway and genome-wide association studies. 4 
Annu. Rev. Public Health 31, 21–36 5 
105  Liu, D.J. and Leal, S.M. (2010) A novel adaptive method for the analysis of 6 
next-generation sequencing data to detect complex trait associations with 7 
rare variants due to gene main effects and interactions. PLoS Genet. 6, 8 
e1001156 9 
106  Lynch, M. and Walsh, B. (1998) Genetics and analysis of quantitative traits, 10 
Sinauer Associates. 11 
107  Hill, W.G. and Zhang, X.-S. (2012) On the pleiotropic structure of the 12 
genotype-phenotype map and the evolvability of complex organisms. 13 
Genetics 190, 1131–7 14 
108  Szymczak, S. et al. (2009) Machine learning in genome-wide association 15 




































Additive genetic variance – the total variance contributed by the additive 9 
effects of each causal variant. 10 
Copy number variant (CNV) – a form of structural variation where there are 11 
alteration in the genome that result in variation in the number of copies of one or 12 
more sections of DNA. 13 
De novo mutation – a genetic mutation that neither parent possessed nor 14 
transmitted. 15 
Epigenetic inheritance – mitotically or meiotically heritable changes in gene 16 
expression or cellular phenotype caused by mechanisms other than changes in 17 
DNA sequence. 18 
Epistasis – the interaction of genes, where the expression of one gene depends 19 
on the presence of one or more other genes. 20 
Fitness – an organism’s ability to survive and reproduce in a particular 21 
environment. 22 
Genetic drift – variation in the frequency of genotypes within a population due 23 
to chance events. 24 
Heritability – proportion of observable differences in a trait among individuals 25 
within a population that is due to genetic differences. 26 
Linkage disequilibrium (LD) – the occurrence in members of a population of 27 
combinations of linked loci in non-random proportions 28 
Minor allele frequency (MAF) – the frequency at which the least common allele 29 
occurs within a given population. 30 
Mutation – the changing of the structure of a gene, resulting in a variant form 31 
which may be transmitted to subsequent generations, that is created by the 32 
alteration of a single base unit of DNA. 33 
Odds ratio – Ratio of the odds of an event occurring in one group to the odds of 34 
it occurring in another group, i.e. the joint probability distribution of two binary 35 
random variables. 36 
Pleiotropy – the production by a single gene of two or more apparently 37 
unrelated effects. 38 
Single nucleotide polymorphism (SNP) – a DNA sequence variation occurring 39 


















BOX 1. The distribution of genetic variants across allele frequency. 8 
The variance explained by a single causal variant depends upon its effect size 9 
and its frequency within the population. Under neutrality and random mating, 10 
the allele frequency distribution is approximately proportional to 1/[p(1-p)] [23] 11 
and the genetic variance contributed by a single variant is 2p(1-p)a2, where p is 12 
the frequency of the causal variant and a is the effect size on an arbitrary scale. 13 
Under a neutral model, this implies that most variants are rare, but most of the 14 
genetic variance is due to common variants [24].  15 
 16 
The effect of directional selection is to increase the amount of variation 17 
explained by rare variants, because natural selection should minimize the 18 
frequency of deleterious variants in the population [24]. Therefore, for any 19 
phenotype, many causal variants will be rare, and the proportion of population-20 
level genetic variance in complex phenotypes attributable to variants across the 21 
allele frequency spectrum will depend upon the strength of selection in our 22 
evolutionary past. The problem is that this is something that we do not know. 23 
Additionally, newly arising mutations can have pleiotropic effects on multiple 24 
phenotypes and the effect (size and / or direction) of a given mutation may not 25 
be the same for all traits. Moreover, each of the traits affected may be associated 26 
with fitness in different ways, and thus held at frequencies that are intermediate 27 
between two phenotypes (e.g. balancing selection).  28 
 29 
The distribution of GWAS findings to date, obtained from the Published GWAS 30 
Catalogue, across allele frequency is shown below for studies from 2008 on a 31 
selection of traits each of which is given a different color. For quantitative traits 32 
(Figure Ia) the absolute effect is plotted against the minor allele frequency, and 33 
for complex common diseases (Figure Ib) the odds ratio is plotted against the 34 
risk allele frequency. Each of the 38 quantitative traits and 43 disease traits are 35 
represented by different colors. There an ascertainment bias in that the power of 36 
detection is proportional to pa2, but it is clear that for each complex trait 37 
variance is contributed from the entire allele frequency spectrum. This highlights 38 
the scarcity of low frequency variants identified by GWAS for quantitative traits 39 
and complex disease in humans. Detecting these variants will require a 40 
combination of greater sample size, better genotyping and improved 41 
phenotyping. 42 
 43 














Box 2. Do we need a new paradigm to dissect complex trait variation?  8 
 9 
"We consider it a good principle to explain the phenomena by the simplest 10 
hypothesis possible." – Ptolemy circa AD 90 11 
 12 
Simpler explanations are, other things being equal, generally better than more 13 
complex ones. The field of quantitative genetics uses a long-standing polygenic 14 
model. Fisher’s infinitesimal model is, per definition, a simplification because 15 
there are not an infinite number of loci, each with a small effect. However, it 16 
allows a statistical treatment and description of the resemblance between 17 
relatives, partitioning of sources of variation and the response to natural or 18 
artificial selection. It may be a century after Fischer, but this paradigm has stood 19 
the test of time. Predictions from this statistical model can be tested empirically 20 
and, by-and-large empirical data are remarkably consistent with this model 21 
[25,106,107].  22 
 23 
We do wish to know the genotypic values at interacting loci (termed by some the 24 
genotype-phenotype map [67]), the differences they create in environmental 25 
variance, and the influence of dominance and epistasis. However, while this 26 
‘genotype-phenotype map’ is conceptually tractable, statistically determining 27 
these effects within a population at thousands of loci is a far from trivial task. 28 
Trading the GWAS assumptions of additivity for more complex assumptions 29 
worsens the problem, as interactive models lose power and there will be a huge 30 
sampling variance on the interactive effects of multiple loci. Most gene-gene and 31 
gene-environment interactions are undetected, but this is a limitation of sample 32 
size rather than the method of analysis.  For example, for two loci of MAF 0.2, one 33 
homozygote has a frequency of 16 in 10,000 so estimating its effects relative to 34 
other genotypes will require large sample sizes. Given the large mutational 35 
target for complex traits, suggestions for the collection of datasets that “contain 36 
phenotypes associated with as many genotype combinations from the common 37 
and/or known allele variants as possible” [67], would likely require greater 38 
sample size than the entire planet to estimate all possible two and higher order 39 
interaction terms, be computationally non-trivial given a finite data set, and 40 
would be an impractical task for gaining conclusions. 41 
 42 
More tractable are the improvements that we outline here, which will then 43 
enable identified regions and their potential pathways to be studied in further 44 
depth. Statistical methods fitting multiple markers [99], gene-set analyses [98], 45 
and machine learning approaches [108] will all complement GWAS findings. 46 
Through fine mapping, target gene identification, and functional identification in 47 
laboratory models [91] we can then better understand the underlying biology of 48 








FIGURE 1. (a) The number of low frequency variants required to explain 7 
the remaining missing heritability for human height and (b) the power to 8 
detect variants that underlie complex common disease with 10,000 cases 9 
and 10,000 matched controls. For (a) the heritability remaining ℎ𝑟
2 for human 10 
height that is not explained by associations with common SNPs was taken to be 11 




, where a is the effect 12 
size in SD (0.15, 0.25, 0.5, or 1) and p is the minor allele frequency of the causal 13 
variants. For (b) the power to detect variants for complex diseases of different 14 
prevalence with 10,000 cases and 10,000 matched controls. 15 
 16 
 17 
FIGURE 2. Identifying additional causal variants and dissecting additional 18 
genetic variation for complex traits. Current limitations (outer circle) and 19 
potential solutions (inner circle) to targeting additional causal variants using 20 
whole genome studies. 21 
 22 
BOX FIGURE I. For quantitative traits (a) the absolute effect is plotted against the 23 
minor allele frequency, and for complex common diseases (b) the odds ratio is 24 
plotted against the risk allele frequency. Each of the 38 quantitative traits and 43 25 
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